Follows people with neurofibromatosis type 2 to study tumors and nerve problems
Follows people with neurofibromatosis type 2 over time with scans and checkups.
Key facts
- Who runs it
- National Institute of Neurological Disorders and Stroke (NINDS)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Natural History Study of Patients With Neurofibromatosis Type 2
- Status
- Recruiting
- People taking part
- 269 people, planned
- Started
- 21 Mar 2008
- Type of study
- Observational
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 8 to 75 with neurofibromatosis type 2 (NF2). They will be followed for up to ten years with yearly check-ups and scans.
- Age
- 8 to 75 years
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of NF2, confirmed by established clinical criteria or genetic testing.
- Biomarker or test result
- NF2 diagnosis by clinical criteria or genetic testing.
Main reasons for not taking part
- A clinically unstable condition, such as Class 3 congestive heart failure, severe chronic renal insufficiency or severe chronic obstructive pulmonary disease
- Cannot have an MRI scan, for example because of an allergy to contrast agents or metal implants such as pacemakers
- Auditory brainstem implants (ABIs) or cochlear implants not approved for NIH scanners
- Severe chronic renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m2), hepatorenal syndrome or post-liver transplantation
- Pregnant at the intake visit
The registry criteria, word for word
Show all 11 criteriaShow less
Who cannot take part
- Cannot have an MRI scan due to an allergy or relative contraindication to MRI contrast agents, prior surgery or implant that involves metal clips or wires, which might be expected to cause tissue damage or produce image artifacts such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, and artificial heart valves
- ABIs or cochlear implants are not approved by the NIH Radiology department for safe use on NIH scanners
- Have a clinically unstable condition that precludes serial clinical and imaging evaluation (i.e. Class 3 congestive heart failure, severe chronic renal insufficiency, severe chronic obstructive pulmonary disease)
- Have severe chronic renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m2), hepatorenal syndrome or post-liver transplantation
- Are pregnant at time of intake visit (women of childbearing age will be tested with a urine pregnancy test)
- Candidates will be excluded if they:
Other criteria
- INCLUSION CRITERIA:; To be eligible for entry into the study, candidates must meet all the following criteria:
- Have the diagnosis of NF2 by established clinical criteria or genetic testing
- Be between the age of 8 and 75
- Have the capacity to undergo serial MRI scanning of the CNS without IV sedation
- Able to give informed consent, or have a parent able to provide informed consent if a child
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 75 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Christina P Hayes, C.R.N.P.Taking people
About the trial
What the trial wants to find out
Objective
Read full original descriptionShow less
With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.
Study Population
A total of 269 participants, ages 8-75, with a clinical or genetic diagnosis of NF2 will participate in this study.
Design
Study participants will be evaluated with a thorough physical and neurologic examination upon enrollment. This initial outpatient evaluation will include magnetic resonance imaging with contrast of brain and spine and blood collection for research use. Participants with measurable hearing will have audiology assessment performed. Participants with untreated vestibular schwannomas will have vestibular assessment performed during the initial visit. Genetic studies performed outside will be acceptable as confirmation of NF2 in enrolled patients. If needed to confirm NF2 with genetic studies, or for research purpose, whole genome/whole exome sequencing may be performed on blood obtained from subjects enrolled in this study. All participants will be evaluated by a speech language pathologist.
Subjects will be followed as outpatients for up to ten years, during which clinical, and radiologic evaluation will be performed annually. Auditory testing will be performed annually for participants with measurable hearing. Participants with initially untreated vestibular schwannomas will be followed annually with vestibular testing. Speech and swallowing reassessments will be repeated if worsening of speech or swallowing is reported. Blood will be collected at each visit for blood biomarker testing
Outcome measures
We hope to understand the biologic basis for speech and swallowing dysfunction in patients with NF2. We will study and report the strength of association of MRI findings, clinical assessments cranial nerve deficits and speech/swallowing dysfunction. We hope to
identify imaging biomarkers of hearing loss in NF2. We will attempt to discover the mode of peripheral neuropathy in patients with NF2. Lastly, we will attempt to discover previously unknown serum biomarkers associated with high tumor burden in NF2.
...
The group in the trial
- Patients
Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2).
- Plain-language title
- Follows people with neurofibromatosis type 2 to study tumors and nerve problemsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT00598351, who can take part
- Record updated
- 16 October 2026